• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Effect of decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消積方) plus chemoembolization on primary liver cancer in patients

    2022-07-20 15:54:08WUTongYANGZhiyunYANGYuyingJIANGYuyongMENGPeipeiLIUHuiminTIANYehongZHANGQiaoli
    關(guān)鍵詞:消積扶正

    WU Tong,YANG Zhiyun,YANG Yuying,JIANG Yuyong,MENG Peipei,LIU Huimin,TIAN Yehong,ZHANG Qiaoli

    WU Tong,YANG Zhiyun,YANG Yuying,JIANG Yuyong,MENG Peipei,LIU Huimin,Department of Integrated Traditional Chinese and Western Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

    TIAN Yehong,Acupuncture and Minimally Invasive Oncology,The Third Affiliated Hospital,Beijing University of Chinese Medicine,Beijing 100029,China;Institute of Acupuncture and Moxibustion,Shaanxi University of Chinese Medicine,Shaanxi 712046,China

    ZHANG Qiaoli,Acupuncture and Minimally Invasive Oncology,The Third Affiliated Hospital,Beijing University of Chinese Medicine,Beijing 100029,China

    Abstract OBJECTIVE:To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消積方,FJXF)plus chemoembolization (TACE) on primary liver cancer(PLC) in patients,and study the underlying mechanism.METHODS:Patients with PLC who met the inclusion criteria were randomized into case group and control group.The case group was treated with FJXF combined with TACE.The control group was treated with TACE alone.The short-term clinical effect was evaluated;liver biochemistry,liver function index and multidrug resistance-associated indicators were detected.RESULTS:FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group (83.3% vs 61.1%).There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group,while no difference between the two groups.The same trend can be observed for transaminase and direct bilirubin in both groups.In the case group,it showed a significant increase for albumin at 8 weeks after treatment,while no change in the control group.Multidrug resistanceassociated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group.CONCLUSIONS:FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC.The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF.Additionally,FJXF didn’t increase the risk of liver damage in the combined therapy.

    Keywords:liver neoplasms;ATP binding cassette transporter,subfamily B,member 1;chemoembolization,therapeutic;Fuzheng Jiedu Xiaoji formula

    1.INTRODUCTION

    Primary liver cancer (PLC) is a common malignancy,particularly in China.Global cancer statistics indicated that PLC was the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide in 2018,with about 841 000 new cases and 782 000 deaths.1The American Cancer Society estimated that in 2020 there was 42 810 new cases and 30 160 deaths of PLC.2China has a high incidence of PLC accounting for 46.6% new cases and 47.1% deaths.1Therefore,active prevention and treatment are of great significance for PLC.However,due to the insidious onset and rapid progression of PLC,only 30% patients benefited in surgical resection and liver transplantation.Most patients have no opportunity of surgery after first diagnosed,they are only treated with palliative care intervention,such as transcatheter arterial chemoembolization (TACE),radiofrequency ablation,cryoablation or molecular targeted drugs.Furthermore,current treatment for PLC did not significantly improve 5-year survival in which multi-drug resistance is an important factor of treatment failure.3Fuzheng Jiedu Xiaoji formula (扶正解毒消積方,FJXF) from Traditional Chinese Medicine (TCM) is a clinically effective empirical prescription of the Center for Integrative Medicine of Beijing Ditan hospital.Our previous clinical study indicated that integrative therapy based on FJXF can control the progression and improve the survival rate for PLC.4Based on the previous studies,this study investigated the clinical effect of FJXF combined with TACE for PLC and elucidated the potential mechanism from the phenotype of multi-drug resistance.

    2.METHODS

    2.1.Patients

    A total of 72 patients with PLC admitted to Beijing Ditan hospital from July 2017 to December 2018 were eligible for the study.The included patients were randomized into case group and control group by random number table in the ratio of 1∶1.The details about baseline demographic and clinical characteristics in the two groups are shown in Table 1.There was no significant difference between the two groups on the baseline data(P >0.05).The study was approved by the Ethics Committee of Beijing Ditan Hospital (Jing Di Lun Ke Zi(2017) No.(011)-01).

    Table 1 Baseline information of the patients between the two groups

    2.2.Inclusion criteria

    (a) Conformed to the diagnostic criteria of“Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Primary Liver Cancer”;5(b)unresectable PLC according to the“2018 practice guidance by the American Association for the Study of Liver Diseases”;6(c) Karnofsky performance score (KPS)≥ 70;(d) aged 35 to 65 years;(e) life expectancy > 3 months;(f) Child-Pugh class A or class B;(g) patients signed the informed consent.

    2.3.Exclusion criteria

    (a) Extrahepatic metastases or other primary malignancies;(b) received chemoradiotherapy before enrolled;(c) uncontrollable serious infection,long-term chronic infection or non-healed wound;(d) critical diseases in heart,lung,kidney or other organs;(e)patients with mental disorder;(f) pregnant or lactating women;(g) had contraindications of arterial embolism;(h) patients unable to cooperate.

    2.4.Treatments

    The patients were treated with TACE alone in the control group and FJXF combined TACE in the case group.

    The operation of TACE is as follows:Seldinger technique was used to insert the catheter through the right femoral artery into the hepatic artery,then the blood supply artery of the tumor was observed with mesenteric angiography.Next,chemotherapeutic drug perfusion was completed after superselection of the blood supply artery of the lesion.Chemotherapeutic drugs included fluorouracil (Shenyang Pharmaceutical Co.,Ltd.,Shenyang,China,500 mg/m2) and Epirubicin (Pfizer S.r.l.,Wuxi,China,40 mg/ m2).Finally,perfusion tissue was embolized with iodized oil,and the embolization was further strengthened with gelatin sponge debris till blood flow slowed down.The dose of the embolization was determined according to the tumor size and vascular density.7,8

    FJXF was taken orally on the first day after TACE treatment.FJXF consisted of Dangshen (Radix Codonopsis) 20 g,Huangqi (Radix Astragali Mongolici) 20 g,Baizhu (Rhizoma Atractylodis Macrocephalae) 15 g,Fuling (Poria) 15 g,Beishashen (Radix Glehniae) 15 g,Maidong (Radix Ophiopogonis Japonici) 15 g,Danggui(Radix Angelicae Sinensis) 15 g,Shudihuang (Radix Reh-manniae Preparata) 15 g,Wugong (Scolopendra)10 g,Qiyeyizhihuagen (Rhizoma Paridis) 15 g and Biejia(Carapax Trionycis) 15 g.The formula was modified with clinical symptoms.Dosages and schedules are as follows:decocted in water for oral administration at a dose of 200 mL twice per day,with 14 d as a cycle for 4 consecutive cycles.It was provided and decocted by the TCM pharmacy of Beijing Ditan Hospital Capital Medical University.

    2.5.Reagents

    Reverse transcription-polymerase chain reaction (RTPCR) kit was from TaKaRa Biotechnology Co.,Ltd.,(Dalian,China,3587A),and rabbit anti-human Pglycoprotein monoclonal antibody was purchased from Jackson ImmunoResearch Laboratories Inc.,(PA,USA,111-035-003).

    2.6.Experimental methods

    Real-time PCR:total RNA was extracted and the firststrand cDNA was synthesized by RT-PCR Kit instructions.The PCR was carried out in a 25 μL reaction system.Glyceraldehyde-3-phosphate dehydrogenase was used as an internal reference,and the ratio was used as the multidrug resistance protein 1 (MDR1) mRNA expression.MDR1 upstream primer was 5’-GGCCTAATGCCGAACACATT-3’,and downstream primer was 5’-CTTCTTCACCTCCAGGCTCA -3’.

    Western blot:the specimens were added with protein lysate,homogenized,placed on ice for 15 min,and centrifuged at 12 000 rpm for 10 min.Then the supernatant was pipetted,loaded to the lane,and separated by electrophoresis,transferred to PVDF membrane for incubation with primary antibody at 4℃overnight,then reacted with secondary antibody at room temperature for 4 h.After that,the specimens were examined with X-ray.Finally,the images were scanned and analyzed using LabWorks software.

    2.7.Observation indicators

    (a) The evaluation of short-term clinical effect according to Response Evaluation Criteria in Solid Tumors(RECIST) 1.1.Complete response (CR) defined as complete disappearance of tumor for more than 4 weeks.Partial response (PR) defined as a decrease of ≥ 30% in the sum of the longest diameter for more than 4 weeks.Stable disease (SD) defined as a reduction of < 30% or increase of < 20% in the sum of the longest diameter.Progressive disease (PD) defined as an increase of ≥ 20%in the sum of the longest diameter or occurrence of new lesions.9Disease control rate (DCR) describes the percentage of patients with advanced cancer in which therapeutic intervention has led to a complete response,partial response,or stable disease.The formula of DCR is as follows:

    (b) Liver-associated biochemistry and function parameters in peripheral blood included alanine aminotransferase (ALT),aspartate transferase (AST),alpha-fetoprotein (AFP),direct bilirubin (DBIL),prealbumin (PAB),albumin (ALB) and international standardized ratio of coagulation (INR).The parameters were detected before treatment,at 1 week and 8 weeks after treatment.

    (c) Indicators associated with multidrug resistance in peripheral venous blood involved in MDR1 and pglycoprotein (P-gp),which were detected before treatment and 8 weeks after treatment,respectively.

    2.8.Statistical analysis

    SPSS statistics (version 22.0) was used for data analysis.The count data was expressed as percentage (%) with χ2test.The measurement data were expressed by mean ±standard deviation () witht-test.A threshold ofPvalue was set at 0.05.

    3.RESULTS

    3.1.Comparison of short-term clinical effect between the two groups

    The DCR was 83.3% in the case group and 61.1% in the control group.There was a significant difference between the two groups (Table 2).

    3.2.Comparison of liver-associated biochemistry and function

    The serum ALT,AST and DBIL levels increased at 1 week after the treatment and returned to pre-treatment levels at 8 weeks after the treatment in each group.Meanwhile,they had no difference between the two groups.AFP decreased significantly at 8 weeks after treatment in each group,while it didn’t show a more significant decrease between case and control group.As to the PBA,there was no change after treatment in the case group,while in the control group it was significantly increased at 1 week after TACE,then returned to pretreatment level at 8 weeks after the treatment.Serum ALB level had no difference at 1 week after treatment in each group.Interestingly,there was a significant elevation for ALB at 8 weeks after treatment in the case group but not in the control group.INR remained stable at all times in each group (Table 3).

    Table 2 Comparison of the short-term clinical effect between the two groups [n (%)]

    Table 3 Comparison of liver biochemistry/function before and after treatment

    3.3.Comparison of MDR1 mRNA expression in both groups

    Before treatment,there was no difference for MDR1 expression between case group and control group.In the case group,the mRNA expression of MDR1 slightly decreased at 8 weeks after treatment compared with before treatment (1.10 ± 0.08vs1.03 ± 0.10,P> 0.05).In the control group,the mRNA expression of MDR1 significantly increased at 8 weeks after treatment compared with before treatment (1.08 ± 0.09vs1.30 ±0.07,P< 0.05).

    3.4.Comparison of P-gp protein expression between in both groups

    Before treatment,there was no difference of P-gp expression between case group and control group.In the case group,P-gp kept unchanged at 8 weeks after treatment compared with before treatment (0.59 ± 0.05vs0.60 ±0.06,P> 0.05).In the control group,P-gp significantly increased at 8 weeks after treatment than before treatment (0.58 ± 0.06vs0.82 ± 0.08,P< 0.05) (Figure 1).

    Figure 1 The protein expression of P-gp detected by Western blot in both groups

    4.DISCUSSION

    There is a high incidence for PLC in China accounting for almost half of worldwide cases.Due to the diversity for risk factors,individual variability and tumor heterogeneity,early diagnosis for PLC is limited.Therefore,most patients are diagnosed in advanced stage with poor therapeutic effect.Although some progress has been made for hepatic arterial chemoembolization,minimally invasive treatment and molecular targeted therapies,the 5-year survival rate for PLC was only 10.1%.10-12

    TCM plays an important role in the treatment of refractory disease,such as cancer.In recent years,the combined treatment of TCM and western medicine for malignant tumors has been widely accepted.In Chinese ancient literature,PLC can be classified into the"accumulation","hypochondriac pain",or“l(fā)iver accumulation".According to the theory of TCM,PLC is induced by long-term combined effects of internal and external factors.The internal factors mainly include liver dysfunction leaded by emotional depression and spleen dysfunction induced by fatigue.The external factors mainly include dampness and heat invading in the liver and gallbladder to form toxicity and stasis.Therefore,the pathogenesis for PLC is characterized with the deficiency complicated with excess so that it is difficult to cure.FJXF,which is the clinically effective empirical prescription of the Center for Integrative Medicine of Beijing Ditan hospital,consists of Dangshen (Radix Codonopsis),Huangqi (Radix Astragali Mongolici),Baizhu (Rhizoma Atractylodis Macrocephalae),etc.The formula has the effects of benefiting qi and blood,promoting blood circulation,removing blood stasis,and softening hardness to dissipate stagnation.A Metaanalysis evaluated the effectiveness and safety of multiple treatments (including TACE combined with TCM,TACE combined with sorafenib,TACE or sorafenib alone) for patients with advanced liver cancer,and the results showed that TACE combined with TCM had the best effect and the lowest incidence of adverse events than other treatments.13In a previous clinical study,we had investigated the effect of the integrative therapy based on FJXF for PLC.The results showed that it can delay disease progression and improve survival rate in patients with PLC.4Consistently,the results in this study showed that the DCR of FJXF combined with TACE in the treatment of patients with PLC was 83.3%and was significantly higher than that of TCEA alone(61.1%).Besides,a previous study found that TACE combined with TCM treatment was beneficial to patients with PLC in improving AST,DBIL,ALB and AFP.14Our study indicated that the levels of ALT,AST and DBIL in both case group and control group were increased transiently at 1 week after treatment,then returned to pre-treatment level at 8 weeks after treatment,which were similar to other studies.15-17Therefore,FJXF didn’t increase risk of liver damage in the combined therapy.As to the hepatic synthetic function,ALB in the case group at 8 weeks after treatment was significantly elevated.We speculated that the treatment of FJXF based on the TACE may be beneficial to the improvement of liver synthetic ability.

    TACE is one of the common treatment methods for patients with advanced liver cancer.This method can achieve a median survival of 11-20 months,however more than 40% of patients with PLC have poor therapeutic effect.18One of critical reasons is the multidrug resistance of hepatoma cell to chemotherapeutic drugs.19-21The overexpression of MDR1 and its encoded protein P-gp is the main causes of tumor resistance.P-gp is the most important member of the ABC transporter family,which can actively pump the hydrophobic drug against the concentration gradient from the inside to the outside of the cell in an ATP energy-dependent manner.22,23Drug resistance of hepatoma cell can also be induced by pumping chemotherapeutic drugs out of the cancer cells.The results of our study showed that the expression of both MDR1 and P-gp significantly increased in the control group after treatment,while kept stable in the case group.It suggests that TACE induced multidrug resistance.Importantly,FJXR alleviated TACE-induced multidrug resistance by the stable expression of MDR1 and P-gp,which is also one of the mechanisms for better therapeutic effect in the treatment of FJXF combined with TACE.

    The results of this study showed that FJXF combined with TACE has a better effect in the treatment of unresectable patients with PLC.Its potential mechanism is probably associated with the stable expression of MDR1 and P-gp through avoiding acquired multidrug resistance induced by TACE treatment.Meanwhile,this combination therapy is convenient for clinical application and universal availability.

    5.REFERENCES

    1.Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018;68:394-424.

    2.Siegel RL,Miller KD,Jemal A.Cancer statistics,2020.CA Cancer J Clin 2020;70:7-30.

    3.Zhou X,Ding J,Li H,et al.Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma.J Cell Mol Med 2020;24:4298-311.

    4.Gu LL,Liu HM,Zhou XB,et al.Efficacy analysis of integrative therapy based on Fuzheng Jiedu Xiaoji formula for primary liver cancer.J Tradit Chin Med 2014;55:576-9.

    5.Zhou J,Sun HC,Wang Z,et al.Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition).LIVER CANCER 2018;7:235-260

    6.Marrero JA,Kulik LM,Sirlin CB,et al.Diagnosis,staging,and management of hepatocellular carcinoma:2018 practice guidance by the American Association for the Study of Liver Diseases.Hepatol 2018;68:723-50.

    7.Grandhi MS,Kim AK,Ronnekleiv-Kelly SM,et al.Hepatocellular carcinoma:from diagnosis to treatment.Surg Oncol 2016;25:74-85.

    8.Han K,Kim JH.Transarterial chemoembolization in hepatocellular carcinoma treatment:Barcelona clinic liver cancer staging system.World J Gastroenterol 2015;21:10327-35.

    9.Schwartz LH,Litiere S,de Vries E,et al.RECIST 1.1-Update and clarification:grom the RECIST committee.Eur J Cancer 2016;62:132-7.

    10.Fu J,Wang H.Precision diagnosis and treatment of liver cancer in China.Cancer Lett 2018;412:283-8.

    11.Lurje I,Czigany Z,Bednarsch J,et al.Treatment strategies for hepatocellular carcinoma -a multidisciplinary approach.Int J Mol Sci 2019;20.

    12.Cyranoski D.China embraces precision medicine on a massive scale.Nat 2016;529:9-10.

    13.Chen QF,Wu PH,Huang T,et al.Efficacy of treatment regimens for advanced hepatocellular carcinoma:a network Meta-analysis of randomized controlled trials.Medicine (Baltimore) 2019;98:e17460.

    14.Wan YM,Li YH,Xu ZY,et al.The effect of transarterial chemoembolization in combination with Kang’ai injection on patients with intermediate stage hepatocellular carcinoma:a prospective study.Integr Cancer Ther 2017;17:477-85.

    15.Chen J,Zhang SL.Study of liver function impairment after TACE in liver cancer.Shi Yong Lin Chuang Yi Yao Za Zhi 2017;21:202-4.

    16.Ma MX,Sun XL,Guo YG,et al.Effect of TACE on liver function indexes in patients with primary liver cancer.Hainan Yi Xue Yuan Xue Bao 2017;23:1705-8.

    17.Zhang SW,Lan Y,Sun YM.Effect of hepatic artery chemoembolization on hepatic function in the treatment of hepatic malignancy.Lin Chuang Yi Yao Wen Xian Za Zhi 2017;4:1011.

    18.Martin S,Fako V,Dang H,et al.PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.J Exp Clin Cancer Res 2020;39.

    19.Buschauer S,Koch A,Wiggermann P,et al.Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatmentin vitro.Oncol Lett 2018;15:4635-40.

    20.Perez-Tomas R.Multidrug resistance:retrospect and prospects in anti-cancer drug treatment.Curr Med Chem 2006;13:1859-76.

    21.Song JE,Kim DY.Conventionalvsdrug-eluting beads transarterial chemoembolization for hepatocellular carcinoma.World J Hepatol 2017;9:808-14.

    22.Roninson IB.The role of the MDR1 (P-glycoprotein) gene in multidrug resistancein vitroandin vivo.Biochem Pharmacol 1992;43:95-102.

    23.Tian QE,De LH,Yan M,et al.Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cellsin vitro.BMC Com-plement Altern Med 2012;12:94.

    猜你喜歡
    消積扶正
    基于自噬探討芪靈扶正清解方抗抑郁作用研究
    Fuzheng Kang' ai decoction (扶正抗癌方) inhibits cell proliferation,migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells
    消積飲治療肺癌的研究概況
    養(yǎng)正消積方劑治療惡性腫瘤作用機制的研究進(jìn)展
    疑難病雜志(2020年2期)2020-12-17 09:17:30
    健脾消積湯治療小兒厭食癥的臨床療效觀察
    畫說中醫(yī)
    UPLC-MS/MS法同時測定貞芪扶正膠囊中10種成分
    中成藥(2017年7期)2017-11-22 07:33:04
    消積散結(jié)丸聯(lián)合血栓通注射液治療脾切術(shù)后門靜脈血栓19例
    扶正解毒湯聯(lián)合調(diào)強放療治療宮頸癌50例
    FOLFOX聯(lián)合健脾消積合劑治療晚期胃癌60例臨床觀察
    亚洲国产av影院在线观看| 王馨瑶露胸无遮挡在线观看| 久久这里只有精品19| 最新的欧美精品一区二区| 男女之事视频高清在线观看 | 美女高潮到喷水免费观看| 久久久久精品人妻al黑| 一级毛片黄色毛片免费观看视频| 在线看a的网站| 久久人妻熟女aⅴ| av网站免费在线观看视频| 欧美日韩亚洲综合一区二区三区_| 免费观看人在逋| 日韩av在线免费看完整版不卡| 国产成人精品久久二区二区91| 欧美xxⅹ黑人| 麻豆av在线久日| 亚洲精品久久久久久婷婷小说| 18在线观看网站| 久9热在线精品视频| 一区二区av电影网| 日本wwww免费看| 麻豆国产av国片精品| 首页视频小说图片口味搜索 | 精品人妻一区二区三区麻豆| 巨乳人妻的诱惑在线观看| 无遮挡黄片免费观看| 成年av动漫网址| 黑人巨大精品欧美一区二区蜜桃| 国产一区有黄有色的免费视频| 在线观看免费视频网站a站| av视频免费观看在线观看| 人人妻人人爽人人添夜夜欢视频| 啦啦啦 在线观看视频| 国产精品一区二区在线观看99| 免费观看人在逋| 免费高清在线观看日韩| 纵有疾风起免费观看全集完整版| 亚洲精品自拍成人| 国产极品粉嫩免费观看在线| 99久久精品国产亚洲精品| 啦啦啦在线观看免费高清www| 国产片内射在线| 国产1区2区3区精品| 97精品久久久久久久久久精品| 在线观看www视频免费| 新久久久久国产一级毛片| 久热这里只有精品99| 国产高清不卡午夜福利| 狠狠婷婷综合久久久久久88av| 亚洲一码二码三码区别大吗| 中文字幕人妻熟女乱码| 免费人妻精品一区二区三区视频| 久久精品熟女亚洲av麻豆精品| 亚洲精品美女久久av网站| 国产福利在线免费观看视频| 欧美亚洲 丝袜 人妻 在线| 这个男人来自地球电影免费观看| 国产在线免费精品| 亚洲一码二码三码区别大吗| 少妇人妻 视频| 中文字幕最新亚洲高清| av国产久精品久网站免费入址| 亚洲精品成人av观看孕妇| 99久久人妻综合| 欧美黄色片欧美黄色片| 色94色欧美一区二区| 久久免费观看电影| 99香蕉大伊视频| 一边亲一边摸免费视频| 欧美乱码精品一区二区三区| 亚洲av片天天在线观看| 亚洲综合色网址| 欧美人与性动交α欧美软件| 少妇粗大呻吟视频| 国产主播在线观看一区二区 | 亚洲欧洲日产国产| 男男h啪啪无遮挡| 黄网站色视频无遮挡免费观看| 亚洲国产精品国产精品| 午夜免费男女啪啪视频观看| 国产精品.久久久| 男女之事视频高清在线观看 | 中文字幕精品免费在线观看视频| 91字幕亚洲| 久久毛片免费看一区二区三区| 满18在线观看网站| 美女大奶头黄色视频| 亚洲天堂av无毛| 国产精品人妻久久久影院| 中文字幕高清在线视频| 亚洲精品一卡2卡三卡4卡5卡 | 国产精品久久久久久精品电影小说| 久热爱精品视频在线9| 亚洲国产精品国产精品| 午夜福利一区二区在线看| 亚洲 国产 在线| 999久久久国产精品视频| 欧美黑人欧美精品刺激| 久久久国产精品麻豆| 亚洲熟女精品中文字幕| 99国产精品一区二区蜜桃av | 亚洲,一卡二卡三卡| 亚洲欧美一区二区三区国产| 我要看黄色一级片免费的| 日韩中文字幕欧美一区二区 | 亚洲国产欧美在线一区| 午夜日韩欧美国产| 亚洲av在线观看美女高潮| 亚洲中文av在线| 久久久精品国产亚洲av高清涩受| 热re99久久国产66热| 久久精品国产a三级三级三级| 看十八女毛片水多多多| 亚洲av成人精品一二三区| 在线观看免费高清a一片| 婷婷成人精品国产| 国产在线视频一区二区| 观看av在线不卡| 午夜福利视频精品| 精品人妻1区二区| 精品国产乱码久久久久久男人| 国产一区二区在线观看av| 中文字幕色久视频| 国产97色在线日韩免费| 国产一区亚洲一区在线观看| av不卡在线播放| 亚洲成人免费电影在线观看 | 亚洲熟女精品中文字幕| 18禁裸乳无遮挡动漫免费视频| 亚洲国产中文字幕在线视频| 伦理电影免费视频| 国产精品国产三级国产专区5o| 在线观看人妻少妇| 视频区欧美日本亚洲| 久久天躁狠狠躁夜夜2o2o | av在线app专区| 国产午夜精品一二区理论片| 一级黄色大片毛片| 日本欧美视频一区| 午夜福利免费观看在线| 99香蕉大伊视频| 中国国产av一级| 少妇 在线观看| 丁香六月天网| 亚洲成av片中文字幕在线观看| videosex国产| 久9热在线精品视频| 青春草亚洲视频在线观看| 高清欧美精品videossex| 黄网站色视频无遮挡免费观看| 国产爽快片一区二区三区| 欧美变态另类bdsm刘玥| 人体艺术视频欧美日本| 日本vs欧美在线观看视频| 中文精品一卡2卡3卡4更新| 国语对白做爰xxxⅹ性视频网站| 精品少妇一区二区三区视频日本电影| 韩国精品一区二区三区| 人体艺术视频欧美日本| 人人妻人人澡人人看| 丁香六月欧美| 激情视频va一区二区三区| av视频免费观看在线观看| 久久久亚洲精品成人影院| 精品欧美一区二区三区在线| 亚洲自偷自拍图片 自拍| 亚洲欧美一区二区三区久久| 欧美av亚洲av综合av国产av| 亚洲人成77777在线视频| 一级毛片 在线播放| 亚洲 欧美一区二区三区| 国产亚洲一区二区精品| 另类亚洲欧美激情| 亚洲欧美精品自产自拍| 少妇人妻久久综合中文| 啦啦啦视频在线资源免费观看| 亚洲成人免费电影在线观看 | 国产熟女午夜一区二区三区| 国产亚洲午夜精品一区二区久久| 亚洲中文字幕日韩| kizo精华| 国产精品 国内视频| 免费久久久久久久精品成人欧美视频| 9热在线视频观看99| 999久久久国产精品视频| 午夜免费男女啪啪视频观看| 天天添夜夜摸| 永久免费av网站大全| 别揉我奶头~嗯~啊~动态视频 | 色视频在线一区二区三区| 麻豆乱淫一区二区| 少妇被粗大的猛进出69影院| 久久九九热精品免费| 91精品伊人久久大香线蕉| 午夜影院在线不卡| 亚洲精品久久久久久婷婷小说| 免费在线观看日本一区| 在线观看www视频免费| 人妻一区二区av| 亚洲精品自拍成人| 久久久精品94久久精品| 男人爽女人下面视频在线观看| 天天影视国产精品| 国产免费福利视频在线观看| 日韩一卡2卡3卡4卡2021年| 咕卡用的链子| 精品亚洲乱码少妇综合久久| 大香蕉久久网| 青草久久国产| 水蜜桃什么品种好| 丝袜美腿诱惑在线| 啦啦啦视频在线资源免费观看| 国产淫语在线视频| 午夜老司机福利片| 在线观看www视频免费| 中文字幕人妻丝袜制服| 欧美精品av麻豆av| 一个人免费看片子| 久久99一区二区三区| 成人影院久久| 三上悠亚av全集在线观看| 国产精品麻豆人妻色哟哟久久| 桃花免费在线播放| 一级毛片我不卡| 日本欧美视频一区| 日韩av不卡免费在线播放| 黄色a级毛片大全视频| 性色av一级| 亚洲精品美女久久av网站| 成人国语在线视频| 中文乱码字字幕精品一区二区三区| 极品少妇高潮喷水抽搐| 午夜福利免费观看在线| 十分钟在线观看高清视频www| 国产成人精品久久二区二区免费| av天堂在线播放| 国产亚洲av片在线观看秒播厂| 国产熟女欧美一区二区| 一本—道久久a久久精品蜜桃钙片| 国产精品久久久久成人av| 巨乳人妻的诱惑在线观看| 久久精品人人爽人人爽视色| 最黄视频免费看| 国产成人免费无遮挡视频| 三上悠亚av全集在线观看| 大陆偷拍与自拍| 久久久久国产一级毛片高清牌| 高清不卡的av网站| 国产深夜福利视频在线观看| 叶爱在线成人免费视频播放| 成人三级做爰电影| 欧美成人午夜精品| 黄色视频不卡| 久久久久视频综合| 丰满饥渴人妻一区二区三| 高清视频免费观看一区二区| 极品人妻少妇av视频| 一边摸一边抽搐一进一出视频| 精品国产一区二区三区四区第35| av网站免费在线观看视频| 多毛熟女@视频| 晚上一个人看的免费电影| 国产成人精品无人区| 99久久综合免费| 1024香蕉在线观看| 成人三级做爰电影| 国产精品久久久av美女十八| 久久久久久亚洲精品国产蜜桃av| 欧美 日韩 精品 国产| 伊人亚洲综合成人网| av国产久精品久网站免费入址| www.999成人在线观看| 男女边吃奶边做爰视频| 国产淫语在线视频| 色综合欧美亚洲国产小说| 国产在线一区二区三区精| 成年人黄色毛片网站| 97人妻天天添夜夜摸| 精品国产乱码久久久久久男人| av国产精品久久久久影院| 久久久欧美国产精品| 色综合欧美亚洲国产小说| 亚洲国产精品国产精品| 久久这里只有精品19| 999精品在线视频| 婷婷色麻豆天堂久久| 国产片特级美女逼逼视频| 成在线人永久免费视频| 亚洲成人手机| 视频区欧美日本亚洲| 50天的宝宝边吃奶边哭怎么回事| 国产成人一区二区在线| 欧美久久黑人一区二区| 国产不卡av网站在线观看| 少妇的丰满在线观看| 欧美+亚洲+日韩+国产| 日韩av不卡免费在线播放| 免费日韩欧美在线观看| 久久久欧美国产精品| 国产极品粉嫩免费观看在线| 999久久久国产精品视频| 成年人黄色毛片网站| 一级黄片播放器| 99精国产麻豆久久婷婷| 精品久久久精品久久久| 黄色视频不卡| 色视频在线一区二区三区| 少妇被粗大的猛进出69影院| www.熟女人妻精品国产| 午夜福利乱码中文字幕| svipshipincom国产片| 国产免费又黄又爽又色| 国产精品人妻久久久影院| 极品少妇高潮喷水抽搐| av片东京热男人的天堂| 亚洲国产欧美日韩在线播放| 后天国语完整版免费观看| 亚洲精品成人av观看孕妇| 男的添女的下面高潮视频| 在现免费观看毛片| 国产av精品麻豆| 黄色毛片三级朝国网站| www.999成人在线观看| 国产日韩一区二区三区精品不卡| kizo精华| 2018国产大陆天天弄谢| 在线观看免费视频网站a站| 亚洲成国产人片在线观看| 亚洲av成人不卡在线观看播放网 | 亚洲一卡2卡3卡4卡5卡精品中文| 建设人人有责人人尽责人人享有的| 交换朋友夫妻互换小说| 丝袜脚勾引网站| 成人亚洲精品一区在线观看| 午夜日韩欧美国产| 最近中文字幕2019免费版| 国产成人精品久久二区二区免费| 成人亚洲欧美一区二区av| 国产成人精品久久二区二区免费| 成人亚洲精品一区在线观看| 欧美日韩国产mv在线观看视频| 色94色欧美一区二区| 久久 成人 亚洲| 欧美变态另类bdsm刘玥| √禁漫天堂资源中文www| avwww免费| 狂野欧美激情性xxxx| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲综合色网址| 国产又爽黄色视频| 亚洲精品乱久久久久久| 国产在线观看jvid| 高清av免费在线| 巨乳人妻的诱惑在线观看| 成年女人毛片免费观看观看9 | 亚洲国产av影院在线观看| 伊人久久大香线蕉亚洲五| 女警被强在线播放| 精品人妻1区二区| 99久久精品国产亚洲精品| 精品人妻一区二区三区麻豆| 欧美黄色淫秽网站| 欧美在线黄色| 欧美少妇被猛烈插入视频| avwww免费| 亚洲欧洲日产国产| 精品人妻在线不人妻| svipshipincom国产片| 80岁老熟妇乱子伦牲交| 欧美少妇被猛烈插入视频| av视频免费观看在线观看| www.熟女人妻精品国产| 80岁老熟妇乱子伦牲交| 国产高清videossex| 蜜桃在线观看..| 中文字幕最新亚洲高清| 99国产精品免费福利视频| 精品一区二区三区av网在线观看 | 女人被躁到高潮嗷嗷叫费观| 一区二区av电影网| 国产野战对白在线观看| 精品久久蜜臀av无| 久久精品熟女亚洲av麻豆精品| www.精华液| 欧美变态另类bdsm刘玥| 黑人欧美特级aaaaaa片| 国产在线免费精品| 国产成人a∨麻豆精品| 欧美日本中文国产一区发布| 亚洲国产欧美网| 五月开心婷婷网| 少妇猛男粗大的猛烈进出视频| 看免费成人av毛片| 日韩制服骚丝袜av| 国产深夜福利视频在线观看| 久久久久视频综合| 久久久精品免费免费高清| 国产片内射在线| 亚洲第一青青草原| 欧美久久黑人一区二区| 亚洲中文av在线| 9191精品国产免费久久| 叶爱在线成人免费视频播放| 亚洲午夜精品一区,二区,三区| 亚洲国产欧美一区二区综合| 丰满饥渴人妻一区二区三| 麻豆国产av国片精品| 男人舔女人的私密视频| 一本色道久久久久久精品综合| 国产精品久久久av美女十八| 黑人猛操日本美女一级片| 18禁国产床啪视频网站| 高清不卡的av网站| 免费观看人在逋| 国产片特级美女逼逼视频| 日韩av在线免费看完整版不卡| 黄网站色视频无遮挡免费观看| 一区在线观看完整版| 中文字幕制服av| 婷婷色综合大香蕉| 午夜免费成人在线视频| 精品欧美一区二区三区在线| 91麻豆精品激情在线观看国产 | 一本久久精品| 伊人亚洲综合成人网| 一边摸一边做爽爽视频免费| 欧美日韩一级在线毛片| 男女午夜视频在线观看| 熟女少妇亚洲综合色aaa.| 国产精品国产av在线观看| 精品一区二区三区av网在线观看 | 精品人妻1区二区| 国产一区亚洲一区在线观看| 国产不卡av网站在线观看| 校园人妻丝袜中文字幕| 人人妻人人澡人人爽人人夜夜| 国产在视频线精品| 久久人妻熟女aⅴ| 亚洲精品一卡2卡三卡4卡5卡 | 一本—道久久a久久精品蜜桃钙片| 制服人妻中文乱码| 欧美变态另类bdsm刘玥| 69精品国产乱码久久久| 免费看av在线观看网站| 99热网站在线观看| 日韩欧美一区视频在线观看| 国产高清国产精品国产三级| 亚洲精品美女久久av网站| av国产久精品久网站免费入址| 午夜福利在线免费观看网站| 久久 成人 亚洲| 亚洲国产日韩一区二区| 免费在线观看日本一区| 亚洲国产日韩一区二区| 校园人妻丝袜中文字幕| 亚洲国产精品国产精品| 亚洲少妇的诱惑av| cao死你这个sao货| 国产片内射在线| 国产野战对白在线观看| 日韩人妻精品一区2区三区| 欧美国产精品va在线观看不卡| 亚洲国产精品999| 欧美国产精品一级二级三级| 国产欧美日韩一区二区三区在线| 男的添女的下面高潮视频| av国产久精品久网站免费入址| 一二三四社区在线视频社区8| 啦啦啦在线观看免费高清www| 国产日韩欧美在线精品| 国产精品三级大全| kizo精华| 高潮久久久久久久久久久不卡| 免费少妇av软件| 精品久久久久久电影网| 亚洲av综合色区一区| 欧美精品一区二区免费开放| 欧美成人午夜精品| 18在线观看网站| 午夜两性在线视频| 久久99精品国语久久久| 亚洲欧美激情在线| 如日韩欧美国产精品一区二区三区| 黄色 视频免费看| 最黄视频免费看| av在线app专区| 久久久久国产一级毛片高清牌| 无遮挡黄片免费观看| 最黄视频免费看| 久久久久久久国产电影| 女警被强在线播放| www.自偷自拍.com| 精品久久久久久电影网| 精品人妻一区二区三区麻豆| 99久久精品国产亚洲精品| 涩涩av久久男人的天堂| 老司机午夜十八禁免费视频| 国产深夜福利视频在线观看| 人人妻人人澡人人看| 亚洲专区中文字幕在线| 99精品久久久久人妻精品| 丝袜在线中文字幕| 免费观看a级毛片全部| 纯流量卡能插随身wifi吗| 99精品久久久久人妻精品| 午夜精品国产一区二区电影| 视频区图区小说| 亚洲图色成人| 最新在线观看一区二区三区 | 亚洲精品一区蜜桃| 成人国语在线视频| 国产又爽黄色视频| 国产精品亚洲av一区麻豆| 亚洲精品国产av蜜桃| 日本一区二区免费在线视频| 午夜精品国产一区二区电影| 国产成人av教育| 免费黄频网站在线观看国产| 自拍欧美九色日韩亚洲蝌蚪91| h视频一区二区三区| 久久九九热精品免费| 性色av一级| 欧美人与性动交α欧美精品济南到| 热re99久久精品国产66热6| 亚洲av欧美aⅴ国产| 亚洲欧美清纯卡通| 欧美激情高清一区二区三区| 我要看黄色一级片免费的| 99国产精品一区二区蜜桃av | 高清欧美精品videossex| 欧美日韩亚洲综合一区二区三区_| 美国免费a级毛片| 51午夜福利影视在线观看| 不卡av一区二区三区| 亚洲av欧美aⅴ国产| 国产精品99久久99久久久不卡| 亚洲激情五月婷婷啪啪| 麻豆乱淫一区二区| 国产一区二区三区av在线| 少妇粗大呻吟视频| 极品人妻少妇av视频| 午夜免费成人在线视频| 啦啦啦在线观看免费高清www| 午夜福利一区二区在线看| 国产不卡av网站在线观看| 黄片播放在线免费| 欧美老熟妇乱子伦牲交| 国产精品一区二区在线不卡| 一区二区日韩欧美中文字幕| 欧美久久黑人一区二区| 90打野战视频偷拍视频| 一本大道久久a久久精品| 久久久久久久久久久久大奶| 精品少妇一区二区三区视频日本电影| 一级,二级,三级黄色视频| 在线观看www视频免费| 国产成人av教育| 涩涩av久久男人的天堂| 免费av中文字幕在线| 亚洲精品美女久久久久99蜜臀 | 波多野结衣av一区二区av| 色婷婷av一区二区三区视频| 男女午夜视频在线观看| 日本vs欧美在线观看视频| 搡老岳熟女国产| av一本久久久久| 国产成人系列免费观看| 久久久国产一区二区| 另类亚洲欧美激情| 亚洲欧美日韩高清在线视频 | 免费高清在线观看日韩| 一级毛片电影观看| 国产91精品成人一区二区三区 | 亚洲欧美精品自产自拍| 亚洲欧美一区二区三区国产| 免费人妻精品一区二区三区视频| 欧美日韩亚洲高清精品| 国产一区二区在线观看av| 国产精品久久久av美女十八| 丰满人妻熟妇乱又伦精品不卡| av视频免费观看在线观看| 黄色a级毛片大全视频| 国产精品一区二区在线观看99| 老司机亚洲免费影院| 又大又爽又粗| 纯流量卡能插随身wifi吗| 成人国产av品久久久| 黄色片一级片一级黄色片| 日本91视频免费播放| 激情五月婷婷亚洲| 啦啦啦 在线观看视频| 天天躁日日躁夜夜躁夜夜| 在线看a的网站| 丰满饥渴人妻一区二区三| 国产国语露脸激情在线看| 日本91视频免费播放| 久久久久精品国产欧美久久久 | 亚洲,欧美,日韩| 亚洲欧美中文字幕日韩二区| 国产精品秋霞免费鲁丝片| 黄片小视频在线播放| 2021少妇久久久久久久久久久| 久久精品久久久久久噜噜老黄| 国产91精品成人一区二区三区 | 91九色精品人成在线观看| 成人黄色视频免费在线看| 午夜福利乱码中文字幕| av电影中文网址| 日韩伦理黄色片| 青春草视频在线免费观看| 久久人人爽av亚洲精品天堂| 亚洲av电影在线进入| 亚洲国产精品成人久久小说| 亚洲图色成人|